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Background: Contrast-enhanced radiographic examinations carry the risk of contrast-associated acute kidney injury
(CA-AKI). While CA-AKI is a well-known complication outside the intensive care unit (ICU) setting, data on CA-AKI in
ICU patients are scarce. Our aim was to assess the incidence and short-term outcome of CA-AKI in a mixed
medical-surgical ICU population.
Methods: We conducted a single-center retrospective analysis between September 2006 and December 2008 on
adult patients who underwent a contrast-enhanced computed tomography for urgent diagnostic purposes. CA-AKI
was defined as either a relative increment in serum creatinine of ≥ 25% or an absolute increment in serum
creatinine of ≥ 0.3 mg/dL within 48 hrs after contrast administration. ICU mortality rates of patients with and
without CA-AKI were compared in univariate and multivariate analyses. The need for renal replacement therapy
(RRT) was also recorded.
Results: CA-AKI occurred in 24/143 (16.8%) patients. Coexisting risk factors for kidney injury, such as sepsis,
nephrotoxic drugs and hemodynamic failure were commonly observed in patients who developed CA-AKI. ICU
mortality was significantly higher in patients with than in those without CA-AKI (50% vs 21%, p = 0.004). In
multivariate logistic regression, CA-AKI remained associated with ICU mortality (odds ratio: 3.48, 95% confidence
interval: 1.10-11.46, p = 0.04). RRT was required in 7 (29.2%) patients with CA-AKI.
Conclusions: In our cohort, CA-AKI was a frequent complication. It was associated with a poor short-term outcome
and seemed to occur mainly when multiple risk factors for kidney injury were present. Administration of ICM
should be considered as a potential high-risk procedure and not as a routine innocuous practice in ICU patients.
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Acute kidney injury (AKI) is a frequent complication in
both general and intensive care unit (ICU) patients, that
significantly contributes to morbidity and mortality [1-5].
Among the multiple causes of hospital-acquired AKI,
administration of iodinated contrast media (ICM) has
been found to be the third commonest one [6], and* Correspondence: christophe.clech@avc.aphp.fr
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reproduction in any medium, provided the orcontrast-associated AKI (CA-AKI) has been reported to
be responsible for a 5.5-fold increased risk of death [7].
In the specific ICU setting, administration of ICM to
patients with otherwise multiple risk factors for AKI (sepsis,
nephrotoxic drugs, and hemodynamic failure) may be even
more deleterious. Paradoxically, few studies [8-14] have fo-
cused on CA-AKI in these high-risk patients, who very fre-
quently undergo contrast-enhanced computed tomography
(CT). Moreover, both the incidence and outcome of CA-
AKI vary widely across studies according to case mix and
definitions of AKI.
Despite CA-AKI being a well-known complication
outside the ICU, the paucity and the discrepancy of data
in the ICU justifies additional data. The aim of this studytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of CA-AKI in a mixed medical-surgical ICU population.
Methods
Study design and patients
This retrospective study was carried out in the medical-
surgical ICU of the Avicenne teaching hospital (Bobigny,
France). All adult patients who required a contrast-
enhanced CT for urgent diagnostic purposes between
September 2006 and December 2008 were eligible for in-
clusion. Patients with coronary or non coronary angiog-
raphy were not considered because they do not
correspond to our usual patient population. Exclusion cri-
teria were: history of chronic kidney disease, AKI with or
without renal replacement therapy (RRT) before adminis-
tration of ICM, and multiple administrations of ICM. For
patients who were admitted more than once to the ICU,
only the first ICU stay was included in the analysis.
The decision to perform a contrast-enhanced CT was left
at the attending physicians’ discretion. During the whole
study period, iso-osmolar media only were used. There
were no written protocols for either CA-AKI prevention or
dosing of ICM. Indications for and modalities of RRT were
also left at the attending physicians’ discretion. No patient
received “prophylactic” RRT after administration of ICM.
The study was approved by the local ethics committee
(Commission Qualité Sécurité et Ethique des Soins, Avicenne
Hospital, Bobigny, France) and conducted in accordance
with the declaration of Helsinki. Since the study implied
no change in patients’ management and data were an-
onymously processed, the need for informed consent was
waived.
Definition of CA-AKI
In the absence of consensual definition criteria, CA-AKI
was defined as either a relative increment in serum creatin-
ine of ≥ 25%, as in many prior reports [15], or as an absolute
increment in serum creatinine of ≥ 0.3 mg/dL (26 μmol/L),
as suggested by the Acute Kidney Injury Network [16],
within 48 hours after administration of ICM.
The term “contrast-associated” instead of “contrast-
induced” AKI was preferred because the development of
AKI in the ICU setting is often of multiple origins, thus
making hazardous to consider the administration of ICM
as the unique cause for AKI. Rather, the nephrotoxicity of
ICM may be cumulative (ie, may occur mainly when other
risk factors for AKI are present).
Data collection
For each patient, the following variables were collected:
– Baseline characteristics: age, gender, SAPS II score,
Mc Cabe class (class 1, no fatal underlying disease;
class 2, underlying disease fatal within 5 years; class 3,underlying disease fatal within 1 year), admission
category (medical, scheduled surgery, or unscheduled
surgery), and comorbidities (diabetes mellitus,
myeloma and other chronic coexisting conditions
defined according to the Knaus criteria [17]),
– Serum creatinine values measured on the CT day
before administration of ICM, and 24 hours and
48 hours thereafter,
– Additional risk factors for AKI occurring within
48 hours before and after administration of ICM:
sepsis, hemodynamic failure and prescription of
potential nephrotoxic drugs (aminoglycosides,
glycopeptides, trimethoprim/sulfamethoxazole,
loop diuretics),
– Presence or absence of preventive measures
(N-acetylcysteine or isotonic crystalloids), and
– Impact of CA-AKI: need for RRT within 48 hours
after administration of ICM, ICU mortality, length
of ICU stay and persistent need for renal support on
ICU discharge.
Endpoints
The primary endpoints were the incidence of CA-AKI
and short-term outcome of CA-AKI (ie, need for RRT
and ICU mortality).
The secondary endpoints were the length of ICU stay,
and persistent need for renal support on ICU discharge.
Statistical analyses
Comparisons between patients with and those without
CA-AKI were based on the Fischer’s exact test for categor-
ical variables and on the Wilcoxon’s test for continuous
variables.
The effect of CA-AKI on ICU mortality was assessed
through a logistic regression model. Specifically, we adjusted
for patients’ baseline severity reflected by the SAPS II score
and for organ dysfunctions before administration of ICM
reflected by the non-renal SOFA score (SOFA - renal com-
ponent). The goodness of fit and the discrimination of the
model were determined by the Hosmer-Lemeshow statis-
tic and the c statistic (area under the curve), respectively.
Results are shown as adjusted odds ratios with their 95%
confidence intervals.
All p values were two-tailed, and a p value < .05 was
considered significant.
Statistical analyses were performed using a statistical




Over the study period, 1639 patients were admitted to our
unit. Two hundred fifty-six (15.6%) CTs were required for
urgent diagnostic purposes, of whom 194 (75.8%) were
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cases, the patient’s data file was incomplete. Finally, 143
patients were considered for analysis (Figure 1).Incidence of CA-AKI and comparison of patients with and
without CA-AKI
CA-AKI occurred in 24/143 (16.8%) patients (Figure 1).
There was no difference in serum creatinine before CT
between patients with and those without CA-AKI but
patients with CA-AKI had more risk factors for AKI
within 48 hours before administration of ICM, such as
sepsis and hemodynamic failure. Preventive measures
were rarely used, without any difference between patients
with and those without CA-AKI.
Within 48 hours after administration of ICM, the rate
of new risk factors for AKI was similar in the two groups
(Table 1).Association of CA-AKI with renal replacement therapy
RRT was initiated in 7/24 (29.2%) patients with CA-AKI
with a median time of 1 day (interquartile range: 0–2)
after CA-AKI onset (Figure 1). Patients with CA-AKI
who received RRT had similar SAPS II scores and serum
creatinine before CT as patients with CA-AKI who did
not receive RRT but had more failing organs before CT
and were more likely to die in the ICU, although statis-
tical significance was not reached (Table 2). No direct
link between administration of ICM and need for RRT1639 patients screened
256 CT for urgent diagnostic purposes 
(15.6%)






143 patients considered for analysis
124 patients with CA-AKI (16.8%)
ICU mortality 50%
7 patients required RRT (29.2%)
ICU mortality 71.4 %
1
CT : computed-tomography ; RRT : renal replacement 
injury
Figure 1 Study flow chart.could be established due to the absence of consensual
indications for RRT and the low number of patients.
In the two surviving patients with CA-AKI who received
RRT, renal function had recovered on ICU discharge.
Association of CA-AKI with mortality
Patients with CA-AKI had a significantly higher crude
ICU mortality rate than patients without CA-AKI (50% vs
21%, p = 0.004) (Figure 1). After adjustment for patients’
severity, CA-AKI remained an independent risk factor for
ICU mortality (Table 3).
Association of CA-AKI with length of ICU stay
Patients with and those without CA-AKI had similar
lengths of ICU stay (median in days, [interquartile range]:
8 [4–22] vs 8 [6–23], p = 0.66). Among survivors, patients
with CA-AKI had a trend towards increased lengths of
ICU stay (median in days, [interquartile range]: 8 [4–18]
vs 18 [7–26], p = 0.08).
Discussion
While CA-AKI has been extensively investigated outside
the ICU setting, few studies on CA-AKI in ICU patients
have been carried out so far. Moreover, these studies
reported discrepant results regarding the incidence and
outcome of CA-AKI according to case mix and defini-
tions of AKI [8–14].
In this work, we did not only assess the incidence of
CA-AKI but we also assessed the outcome of patients in1 patients excluded :
History of chronic kidney disease n=5
RRT before contrast-enhanced CT n=25
Multiple contrast-enhanced CT n=10
Incomplete patients’ data files n=11
19 patients without CA-AKI
ICU mortality 21%
7 patients not requiring RRT (70.8%)
ICU mortality 41.2%
therapy ; CA-AKI : contrast induced acute kidney
Table 1 Differences between patients with and those without contrast-associated acute kidney injury (CA-AKI)
No CA-AKI N = 119 CA-AKI N = 24 P
Age (yrs) 61 [49–73] 63 [53–78] 0.33
Male sex 74 (62.2) 15 (62.5) 0.98
SAPS II score 40 [28–57] 57 [41–78] 0.001
Admission category
medical 83 (69.8) 14 (58.3) 0.22
scheduled surgery 11 (9.2) 1 (4.2)
unscheduled surgery 25 (21) 9 (37.5)
Mc Cabe class
1 65 (54.6) 9 (37.5) 0.08
2 38 (31.9) 8 (33.3)
3 16 (13.5) 7 (29.2)
Serum creatinine (μmol/L) before administration of ICM 87 [68–120] 90 [64–128] 0.91
Preventive measure 6 (5) 1(4.2) 1
Risk factors for AKI within 48 hrs before ICM administration 64 (53.8) 20 (83.3) 0.01
diabetes mellitus 24 (20.2) 4 (16.7) 1
myeloma 0 (0) 1 (4.2) 0.17
nephrotoxic drugs 22 (18.5) 7 (29.2) 0.26
sepsis 48 (40.3) 16 (66.7) 0.02
hemodynamic failure 14 (11.8) 11 (45.8) < 0.001
New risk factors for AKI within 48 hrs after ICM administration 36 (30.2) 7 (29.2) 1
nephrotoxic drugs 19 (16) 4 (16.7) 1
sepsis 30 (25.2) 7 (29.2) 0.63
hemodynamic failure 4 (3.4) 1 (4.2) 0.9
Results are expressed as median [interquartile range] or as number (percent).
ICM, iodinated contrast media.
Table 2 Differences between patients with contrast-associated acute kidney injury who received and who did not
receive renal replacement therapy (RRT)
No RRT N = 17 RRT N = 7 P
SAPS II 58 [44–72] 50 [37–92] 0.97
Non-renal SOFA score before ICM administration 5 [4-6] 7 [5-9] 0.24
Serum creatinine (μmol/L) before ICM administration 90 [63–128] 83 [66–198] 0.80
Risk factors for AKI within 48 hrs before ICM administration 14 (82.3) 6 (85.7) 1
diabetes mellitus 3 (17.7) 1 (14.3) 1
myeloma 1 (5.9) 0 (0) 1
nephrotoxic drugs 5 (29.4) 2 (28.6) 1
sepsis 10 (58.9) 6 (85.7) 0.37
hemodynamic failure 7 (41.2) 4 (57.1) 0.76
New risk factors for AKI within 48 hrs after ICM administration 4 (23.5) 3 (42.9) 0.37
nephrotoxic drugs 3 (17.7) 1 (14.3) 1
sepsis 4 (23.5) 3 (42.9) 0.63
hemodynamic failure 0 (0) 1 (14.3) 0.3
Preventive measure 0 (0) 1 (14.3) 0.3
ICU mortality 7 (41.2) 5 (71.4) 0.37
Results are expressed as median [interquartile range] or as number (percent).
ICM, iodinated contrast media; AKI, acute kidney injury; non-renal SOFA score, SOFA score - renal component.
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Table 3 Factors independently associated with intensive
care unit mortality
Variable OR 95% CI P
CA-AKI 3.48 1.10-11.46 0.04
SAPS II score, per point 1.03 1.01-1.05 0.03
Non-renal SOFA score, per point 1.38 1.12-1.71 0.003
Hosmer-Lemeshow chi square = 9.7, p = 0.20, c statistic = 0.80.
CA-AKI, contrast-associated acute kidney injury; OR, odds ratio; CI,
confidence interval.
Non-renal SOFA score, SOFA score - renal component.
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CA-AKI to be a frequent event in our mixed medical-
surgical population. It was associated with a high risk of
ICU death, and tended to increase the length of ICU
stay. These results are consistent with the ones of Hoste
et al [9]. Remarkably, the ICU mortality in CA-AKI
patients observed in this study (50%) was about twice
the ICU mortality of all-cause AKI reported in recent
studies evaluating the prognosis of AKI, as defined by
RIFLE criteria [1,3,4]. Another remarkable finding was
that most patients with CA-AKI had multiple risk fac-
tors for AKI, lending support to the concept of cumula-
tive toxicity (rather than absolute toxicity) of ICM. In
addition, RRT failed to reverse renal dysfunction and re-
duce mortality in CA-AKI patients. Accordingly, admin-
istration of ICM should be considered as a potential
high-risk procedure and not as a routine innocuous
practice in ICU patients, and the technical possibility to
put patients on RRT “if necessary” should not be used as
an argument to force radiologists to administer ICM.
Although emphasizing the significant burden of CA-
AKI in ICU patients, our study has potential limitations.
First, we were not able to accurately assess the benefit/risk
ratio of contrast-enhanced CT since precise indications of
CT and subsequent therapeutic changes were hazardous
to extract retrospectively from patients’ files. This import-
ant issue deserves further investigation. Second, we did
not examine the influence of the volume of ICM and ap-
plication of preventive measures on the incidence of CA-
AKI. The volume of ICM, which has been shown to play a
role in the development of CA-AKI, [15] could not be
retrospectively retrieved. Regarding preventive measures,
they were too rarely used, probably due to the emergency
context. It must be stressed, anyhow, that volume expan-
sion and hemodynamic optimization are probably of ut-
most importance to reduce the risk of CA-AKI, even
though the impact of preventive measures in ICU patients
needs to be further evaluated. Third, we did not assess the
impact of repeated administrations of ICM because of the
many confounding factors. Fourth, fluid balance and hemo-
dilution which could have lead to underestimation of CA-
AKI incidence (by limiting serum creatinine increase) were
not collected. Yet, it must be noticed that this limitationpertains to all studies using the glomerular filtration rate
criteria of AKIN or RIFLE definitions. Finally, one may
argue that the absence of a “control” group not receiving
ICM hinders any definite conclusion as to the actual tox-
icity of ICM. However, the aim of this study was not to es-
tablish the absolute toxicity of ICM but to determine the
incidence of CA-AKI and identify potential coexisting risk
factors that are important to consider before exposing
patients to ICM. Moreover, it must be stressed that patients
are undoubtedly their best controls, and that random varia-
tions in serum creatinine among “control” patients, that
would equate to AKI [18], may expose to biased estimation
of the true risk associated with ICM and erroneous infer-
ence. In addition, the chronological order of events, the
time constraint of 48 hours, and the similar rate of new risk
factors for renal dysfunction in patients with and without
CA-AKI suggest a cause-effect relationship between admin-
istration of ICM and AKI.
Conclusions
In our mixed medical-surgical ICU population requiring
contrast-enhanced CTs for urgent diagnostic purposes,
CA-AKI was a frequent and severe complication. In keep-
ing with the few available retrospective data, our study
indicates that the administration of ICM in patients with
otherwise multiple risk factors for AKI should be consid-
ered with caution, all the more as CA-AKI may not only
impair short-term but also long-term prognosis [9,19].
Large prospective trials on ICU patients are warranted
to more accurately assess the benefit/risk ratio of contrast-
enhanced CTs, the role of preventive measures, and the
impact of repeated administrations of ICM.
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